Cyclacel Pharmaceuticals (CYCC) Scheduled to Post Quarterly Earnings on Wednesday

Cyclacel Pharmaceuticals (NASDAQ:CYCCGet Rating) is scheduled to announce its earnings results after the market closes on Wednesday, May 11th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter.

Cyclacel Pharmaceuticals (NASDAQ:CYCCGet Rating) last announced its quarterly earnings data on Monday, March 28th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.17. During the same period last year, the business posted ($1.34) EPS. On average, analysts expect Cyclacel Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Shares of NASDAQ:CYCC opened at $1.97 on Thursday. Cyclacel Pharmaceuticals has a 1-year low of $1.79 and a 1-year high of $7.95. The firm has a market capitalization of $19.68 million, a PE ratio of -0.92 and a beta of 1.39. The business’s 50 day moving average is $2.74 and its 200-day moving average is $3.52.

Several institutional investors have recently bought and sold shares of CYCC. Morgan Stanley lifted its position in shares of Cyclacel Pharmaceuticals by 21.3% during the 2nd quarter. Morgan Stanley now owns 121,275 shares of the biotechnology company’s stock worth $718,000 after buying an additional 21,275 shares during the period. Geode Capital Management LLC lifted its position in shares of Cyclacel Pharmaceuticals by 15.9% during the 3rd quarter. Geode Capital Management LLC now owns 58,934 shares of the biotechnology company’s stock worth $310,000 after buying an additional 8,074 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of Cyclacel Pharmaceuticals during the 3rd quarter worth approximately $74,000. Millennium Management LLC bought a new position in Cyclacel Pharmaceuticals in the 4th quarter valued at $39,000. Finally, Schonfeld Strategic Advisors LLC raised its position in Cyclacel Pharmaceuticals by 210.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 322,373 shares of the biotechnology company’s stock valued at $1,254,000 after purchasing an additional 218,448 shares during the last quarter. Institutional investors and hedge funds own 32.41% of the company’s stock.

Several research firms recently commented on CYCC. Zacks Investment Research downgraded Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 21st. StockNews.com began coverage on Cyclacel Pharmaceuticals in a research report on Thursday. They set a “sell” rating for the company.

Cyclacel Pharmaceuticals Company Profile (Get Rating)

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.

Further Reading

Earnings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.